This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:
Talen Energy ($TLN) Expands Natural Gas Fleet
Talen Energy ($TLN) announced it will acquire three natural gas power plants in Ohio and Indiana from Energy Capital Partners, adding about 2.6 gigawatts of capacity to its portfolio. The deal includes the Waterford, Darby, and Lawrenceburg plants and significantly expands Talen’s footprint in the PJM power market, a region seeing rising electricity demand from data centers and large commercial users.
According to the company, the $3.45 billion transaction will be paid with a mix of cash and stock and is expected to meaningfully boost free cash flow per share once completed. Talen said the plants are modern, efficient, and well-positioned to provide steady “baseload” power, helping diversify its fleet and support long-term growth. Management also highlighted that the acquisition builds on earlier gas asset purchases made in 2025 and fits its broader strategy of scaling generation while keeping leverage in check.
The deal is expected to close in the second half of 2026, subject to regulatory approvals.
Stock Price Reaction:
$TLN shares jumped about 11% on the announcement day, but the rally was short-lived. The stock gave up all of those gains the following day, ending flat versus pre-announcement levels.
Corvus ($CRVS) Shares Explode on Strong Early Eczema Drug Data
Corvus Pharmaceuticals said its experimental pill soquelitinib showed strong results in a Phase 1 study for atopic dermatitis (eczema), including in patients who did not respond well to existing treatments.
In simple terms, patients taking soquelitinib saw much clearer skin compared with placebo, and results improved the longer they stayed on the drug. In the latest group of patients, 75% reached a major improvement level (EASI-75) after eight weeks, with some achieving near-clear or fully clear skin.
The drug also appeared safe, with no serious side effects reported.
Corvus said the results were consistent across multiple patient groups, including those who previously failed treatments like biologics or JAK inhibitors. Based on this data, the company plans to start a larger Phase 2 trial in early 2026 to further test the drug.
Stock Price Reaction:
$CRVS shares surged about 165% after the announcement.
AeroVironment ($AVAV) Hit by U.S. Government Stop-Work Order on SCAR Program
AeroVironment said the U.S. government has issued a stop-work order on part of its SCAR satellite communications program, triggering a sharp negative reaction in the stock.
AeroVironment is best known for its military drones and autonomous systems, including small unmanned aircraft and loitering munitions used by the U.S. military and allies. The company also develops advanced communications and sensing technologies that support modern battlefield operations, including satellite-based systems.
According to the company, the stop-work order applies to its Other Transaction Agreement (OTA) related to the delivery of BADGER phased-array antenna systems for the Satellite Communication Augmentation Resource (SCAR) program. The pause was issued by mutual agreement between AeroVironment and the U.S. government.
In practical terms, this does not mean the program is canceled. Instead, the stop-work order gives both sides time to renegotiate the contract under new requirements. AeroVironment said the revised agreement is expected to move to a firm-fixed price structure, which typically shifts more cost risk onto the contractor but also provides clearer revenue visibility once finalized.
The company stated it expects to continue delivering capabilities and products for the SCAR program after the amendment is completed, signaling that the relationship with the U.S. government remains intact. However, the pause introduces short-term uncertainty around timing, revenue recognition, and margins for this specific program.
Stock Price Reaction:
$AVAV shares fell about 16% on the news, as investors reacted to the near-term uncertainty created by the stop-work order, despite management emphasizing that negotiations are ongoing and the program is expected to continue.
This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.
